What is the appropriate treatment protocol for an acute infective exacerbation of chronic obstructive pulmonary disease (COPD)?

Treatment Protocol for Acute Infective Exacerbation of COPD

For acute infective exacerbations of COPD, initiate treatment with short-acting bronchodilators (β2-agonists with or without anticholinergics), systemic corticosteroids, and antibiotics when bacterial infection is indicated by increased sputum purulence and/or volume. 1

Initial Assessment and Classification

Classify the exacerbation severity to guide treatment intensity 1:

• Mild exacerbation: Treat with short-acting bronchodilators only 1
• Moderate exacerbation: Requires short-acting bronchodilators plus antibiotics and/or oral corticosteroids 1
• Severe exacerbation: Requires hospitalization or emergency department visit; may involve acute respiratory failure 1

Critical step: Rule out alternative diagnoses including acute coronary syndrome, congestive heart failure, pulmonary embolism, and pneumonia, as these commonly coexist with COPD 1.

Bronchodilator Therapy

Short-acting inhaled β2-agonists (such as albuterol), with or without short-acting anticholinergics (ipratropium), are the initial bronchodilators for acute exacerbations 1.

• Administer via metered-dose inhaler with spacer or hand-held nebulizer 1
• Dosing: 2 puffs every 2-4 hours as needed 1
• Avoid methylxanthines (theophylline) due to side effects without added benefit 1

Systemic Corticosteroid Therapy

Systemic corticosteroids improve lung function (FEV1), oxygenation, shorten recovery time, and reduce hospitalization duration 1.

Outpatient/Moderate Exacerbations:

• Prednisone 30-40 mg orally daily for 10-14 days 1

Hospitalized Patients:

• If oral intake tolerated: Prednisone 30-40 mg orally daily for 10-14 days 1
• If unable to tolerate oral: Equivalent intravenous dose for up to 14 days 1

Note: Exacerbations with increased sputum or blood eosinophils may be more responsive to systemic steroids 1.

Antibiotic Therapy

Antibiotics, when indicated, shorten recovery time and reduce risk of early relapse, treatment failure, and hospitalization duration 1.

Indications for Antibiotics:

Prescribe antibiotics when patients demonstrate increased sputum purulence and/or increased sputum volume 1, 2.

Antibiotic Selection Based on Severity:

Outpatient/Mild-Moderate Exacerbations 1:

• First-line: Amoxicillin/ampicillin, cephalosporins, or doxycycline
• Macrolides (azithromycin, clarithromycin) are acceptable but have lower predicted efficacy 3
• If prior antibiotic failure: Amoxicillin/clavulanate or respiratory fluoroquinolones

Hospitalized/Severe Exacerbations 1:

• Amoxicillin/clavulanate OR
• Respiratory fluoroquinolones (levofloxacin, moxifloxacin, gatifloxacin)
• If Pseudomonas or Enterobacteriaceae suspected: Consider combination therapy 1

Evidence shows fluoroquinolones, cefditoren, and high-dose amoxicillin/clavulanate have the highest predicted clinical efficacy (89-90% for mild-moderate, 80-88% for severe exacerbations) 3.

Oxygen Therapy (for Severe Exacerbations)

Goal: Maintain PaO2 ≥60 mmHg (8 kPa) or SpO2 ≥90% to prevent tissue hypoxia 1.

• Deliver via nasal cannula or Venturi mask 1
• Monitor arterial blood gases for PaO2, PaCO2, and pH 1
• Prevention of tissue hypoxia takes precedence over CO2 retention concerns 1
• If CO2 retention with acidemia develops, consider noninvasive ventilation 1

Ventilatory Support

Noninvasive ventilation (NIV) should be the first mode of ventilation for acute respiratory failure 1.

Indications for ICU/Special Care Admission 1:

• Impending or actual respiratory failure
• Other end-organ dysfunction (shock, renal, hepatic, or neurological disturbance)
• Hemodynamic instability

Hospital Discharge Planning

Before discharge 1:

• Initiate maintenance therapy with long-acting bronchodilators as soon as possible
• Implement appropriate measures for exacerbation prevention
• Consider pulmonary rehabilitation within 3 weeks after discharge 1

Common Pitfalls to Avoid

• Do not use methylxanthines as they provide minimal benefit with significant side effects 1, 4
• Do not prescribe antibiotics indiscriminately; reserve for patients with purulent sputum or increased sputum volume 1
• Do not delay NIV in patients with acute respiratory failure; it should be first-line ventilatory support 1
• Do not use macrolides as first-line in severe exacerbations due to lower efficacy compared to fluoroquinolones or amoxicillin/clavulanate 3

Expected Recovery Timeline

Symptoms typically last 7-10 days, though some exacerbations persist longer 1. At 8 weeks, 20% of patients have not recovered to their pre-exacerbation state 1, emphasizing the importance of appropriate initial treatment and follow-up.